There still needs to be more education around what real-world evidence is, explained Jason Harris, associate director of policy and programs at National Health Council.
There still needs to be more education around what real-world evidence is, explained Jason Harris, associate director of policy and programs at National Health Council.
Transcript
What recommendations did the National Health Council come out with in its white paper on real-world evidence?
Recently, it’s been a real-world evidence year, if you will. We hosted a roundtable to solicit the patient perspective. We had close to 50 people in the room, about 15 experts from your more industry perspective and then about 30 patient organizations to just figure out what their concerns were, what their thoughts were, did they know about it. What we really learned from that is that overall, the concept is something that we need more education on, but once it’s explained and understood, it’s certainly something that patient organizations want to be involved in and we want to make sure that the ship doesn’t leave without insuring that perspective.
As you work with patients on real-world evidence, are you finding areas where their perceptions were not lined up with reality?
I think it’s a really good point. Overall, when we talk about the concept of what real-world evidence is and a patient hears that, they think for the most part it makes sense that it would be done because we are thinking of this high-tech era where we can use everything. It’s that understanding of well in healthcare, we are a little bit behind in terms of how we do things and so they were surprised that it wasn’t being done and that we weren’t quite there yet once they understood the concept.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More